What is Triple G Capsules?
Retatrutide is a synthetic 39-amino-acid peptide with a C20 fatty-acid side chain that extends the half-life through albumin binding. It simultaneously activates the receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon. In capsule form the substance comes in a constant amount per capsule, which makes standardised test series without reconstitution easier.
More data in the lexicon entry on Retatrutid.
State of research
All published clinical data on retatrutide come from trials with weekly injection, including the phase II trial in the New England Journal of Medicine (2023) and the ongoing phase III TRIUMPH programme. A capsule form has not been studied clinically.
That is exactly the research question: peptides of this size are rapidly degraded and poorly absorbed in the gut. Semaglutide only became oral with an absorption enhancer. Capsules therefore suit experiments on stability, release and degradation in digestion models.
Status and quality
Retatrutide is not approved as a medicine and is in phase III trials. Peptidkauf sells Retatrutide Capsules solely as a research reagent for laboratory and in-vitro use and gives no dosing or application advice.
An independent laboratory tests every batch for identity and content before it goes on sale; the reports and their verification keys are in the lab report archive. Store the capsules dry, protected from light and at room temperature; no reconstitution is needed.
Related products and articles
The lyophilised form is retatrutide. Comparisons: retatrutide vs. tirzepatide, retatrutide vs. semaglutide.
